On Apr. 23, 2021, the NIH announced that a study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination had begun enrolling participants at the NIH Clinical Center in Bethesda, Maryland. The single-site study aimed to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions.